efegatran has been researched along with gyki 14166 in 3 studies
| Studies (efegatran) | Trials (efegatran) | Recent Studies (post-2010) (efegatran) | Studies (gyki 14166) | Trials (gyki 14166) | Recent Studies (post-2010) (gyki 14166) |
|---|---|---|---|---|---|
| 43 | 3 | 0 | 12 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagdy, D; Bajusz, S; Barabás, E; Szabó, G; Széll, E | 1 |
| Bagdy, D; Bajusz, S; Barabas, E; Dioszegi, M; Fittler, Z; Horvath, G; Juhasz, A; Szabo, G; Szell, E; Tomori, E | 1 |
| Callas, DD; Fareed, J | 1 |
3 other study(ies) available for efegatran and gyki 14166
| Article | Year |
|---|---|
In vivo anticoagulant and antiplatelet effect of D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H.
Topics: Animals; Anticoagulants; Bleeding Time; Blood Coagulation; Cardiovascular System; Dogs; Infusions, Intravenous; Injections, Intramuscular; Injections, Intravenous; Injections, Subcutaneous; Male; Oligopeptides; Platelet Aggregation Inhibitors; Platelet Count; Rabbits; Rats; Respiration; Thrombin | 1992 |
Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H.
Topics: Animals; Anticoagulants; Blood Coagulation Tests; Cattle; Dogs; Fibrinolysis; In Vitro Techniques; Oligopeptides; Rabbits | 1990 |
Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
Topics: Antifibrinolytic Agents; Antithrombin III; Antithrombins; Aprotinin; Arginine; Binding Sites; Boron Compounds; Enzyme Activation; Fibrinolysis; Heparin; Hirudins; Humans; Oligopeptides; Peptide Fragments; Pipecolic Acids; Protein C; Recombinant Proteins; Sulfonamides; Thrombin | 1995 |